LANI positive results

Shows no one knows what the frig is going on.


Biota Pharma announces positive results from phase 2 IGLOO trial of laninamivir octanoate

Atlanta Tuesday, August 05, 2014, 14:00 Hrs [IST] Biota Pharmaceuticals, a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening viral respiratory infectious diseases, announced top-line data from a randomised, double-blind, placebo-controlled, parallel-arm phase 2 clinical trial comparing the safety and efficacy of a 40 mg and 80 mg dose of laninamivir octanoate (LANI) to placebo. The trial, referred to as IGLOO, enrolled 639 patients across 12 countries in the Northern and Southern Hemisphere from June 2013 to April 2014. Of the 639 patients enrolled, 248, or 39 per cent, had PCR confirmed influenza A or B virus and were included in the intent-to-treat efficacy analyses. Approximately 75 per cent and 19 per cent of the influenza-confirmed patients were infected with influenza A H1N1 2009 and H3N2, respectively, with 6 per cent being infected with influenza B. As compared to placebo, neither the 40 mg or 80 mg cohort achieved a statistically significant reduction in the median time to alleviation of influenza symptoms as measured by the Flu-iiQ patient-recorded outcome questionnaire (p=0.248 and p=0.776, respectively), which was the primary endpoint of the study. The median time to alleviation of influenza symptoms was 102.3 hours for the 40 mg cohort and 103.2 hours for the 80 mg cohort, as compared to 104.1 hours for the placebo cohort.........

http://www.pharmabiz.com/NewsDetails.aspx?aid=83328&sid=2